Elite in Atrial Septal Defect (ASD)

Piotr S. Podolec

Prądnicka Str. 80, 
Krakow, MA, PL 
Elite in Atrial Septal Defect (ASD)
Prądnicka Str. 80, 
Krakow, MA, PL 
OverviewLocationsClinical Research

Overview

Piotr Podolec practices in Krakow, Poland. Mr. Podolec is rated as an Elite expert by MediFind in the treatment of Atrial Septal Defect (ASD). His top areas of expertise are Atrial Septal Defect (ASD), Dilated Cardiomyopathy (DCM), Carotid Artery Disease, Stent Placement, and Angioplasty.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles in the study of Atrial Septal Defect (ASD).

Gender
Male

Locations

Prądnicka Str. 80, Krakow, MA 31202, Poland
Other Locations
St. Ann St. 12, Krakow, MA 31008, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Istaroxime
Study Phase: Phase 2
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

255 Total Publications

Prothrombotic fibrin clot phenotype characterized patients with patent foramen ovale following cerebral embolism.
Prothrombotic fibrin clot phenotype characterized patients with patent foramen ovale following cerebral embolism.
Journal: Kardiologia polska
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Podolec's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 14 Advanced Conditions
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile